People who take statins have a significantly reduced risk of developing venous thromboembolism, according to a major new analysis by British experts.
The risk for statins users is between 15 to 25% less than that faced by others, according to the metanalysis conducted reported in The Lancet Haematology.
The analysis involved some 36 studies involving more than 3.2 million people.
One of the researchers, Dr Setor Kunutsor, from Bristol University, said: “Currently, statins are only approved for lipid lowering in the primary and secondary prevention of cardiovascular disease.
“But they have shown great promise beyond their established lipid-lowering effects and these include potential beneficial impact on multiple disease conditions.
“These results provide an extensive body of evidence on the clinical benefit of statin in the occurrence of venous thromboembolism and may support a true protective effect.”
Fellow researcher Professor Kamlesh Khunti, of Leicester University, said: “These findings underscore a potential beneficial role of statin therapy on VTE in addition to its established role in cardiovascular disease prevention.”
Source: Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis The Lancet Haematology 12 January 2017
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.